Novartis psoriasis drug tops J&J's Stelara in late-stage study

December 12, 2014 7:09 AM

3 0

ZURICH (Reuters) - Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara.

Results of the late-stage Phase IIIb study involving 679 patients with moderate to severe plaque psoriasis found those taking Cosentyx achieved clear or almost clear skin after 16 weeks of treatment.

Read more

To category page